GT Biopharma (OTCQB: GTBP), an immuno-oncology company focused on innovative therapies based on the company’s proprietary TriKE(TM) technology platform, has released the pricing of its recent underwritten public offering of 4,300,000 units. The offering will be priced at $5.50 per unit or prefunded unit, with a unit consisting of one share of the company’s common stock and one warrant to purchase one share of its common stock. The company anticipates gross proceeds from the public offering to reach an estimated $23.6 million customer deductions. In the announcement, the company noted that it has also granted a 45-day over-allotment options to the underwriters that allows for the purchase of an additional 645,000 units. For this offering, the company may issue a prefunded unit in lieu of a unit. GT Biopharma anticipates the offering to close on Feb. 16, 2021; the offering will be subject to customary closing conditions. In addition to announcing the public offering pricing, GT Biopharma announced that it has been approved for listing common stock on the Nasdaq Capital Market, trading under its existing ticker symbol, GTBP (“GTBP”) at the opening of market hours on Thursday, Feb. 11, 2021. Roth Capital Partners and Dawson James Securities, Inc. are acting as joint book-running managers for the offering.
To view the full press release, visit https://ibn.fm/z1Ycl
About GT Biopharma Inc.
GT Biopharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE(TM) NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system natural killer cells (“NK cells”). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. For more information about the company, please visit www.GTBiopharma.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.